INTRODUCTION
Haematopoietic cell determination is instructed by transcription factors such as the Ets-domain transcription factor PU.1 (Sfpi1, Spi1). PU.1 levels are very important for development of various blood lineages.
1 PU.1 is expressed at threshold levels in hematopoietic stem and progenitor cells (HSPCs). Highest expression is within monocytes, intermediate levels in granulocytes and lower levels in lymphocytes. 1 Erythroid progenitors undergo progressive silencing of PU.1 level that if it is not completed results in acute myeloid leukemia (AML).
2 PU.1 expression is determined by interactions of its promoter with upstream regulatory element (URE) at À 14 kb relative to transcription start. 3 Disruption of PU.1 gene in mouse is lethal due to the block of the majority of blood cell development, whereas the deletion of URE (PU.1 ure/ure ) downregulates PU.1 to 20% and promotes AML (marked by clonal accumulation of myeloid c-Kit þ Mac-1 low Gr-1 low blast cells) preceded by preleukaemic phase at 2-3 months (marked by two-fold increase of c-Kit þ precursors, Gr-1 þ granulocytes and splenomegaly). 4 Indeed, the PU.1 ure/ure AML displays clonal features characterized by recurring chromosomal abnormalities and is retransplantable into immunodeficient recipients. 4 PU.1 is negatively regulated posttranscriptionally by micro-RNA(miR)-155. 5 Constitutive expression of miR-155 in HSPCs downregulates PU.1 and causes a phenotype resembling AML. 6 While PU.1 transcripts are directly targeted by miR-155, the miR-155 Host Gene (Mir-155hg) is itself transcriptionally activated by temporal PU.1 occupation in HSPCs. 7 This cross-regulation establishes a regulatory loop providing a mechanism for precise regulation of PU.1 expression. Notably, disruption of this finely tuned loop may contribute to AML pathology. 8 Mir-155hg is transcriptionally activated by the Myeloblastoma protein (Myb) 9 whose primary function is to stimulate progenitor cell proliferation and impede differentiation. Expression of Myb must be downregulated during cell maturation. 10 Tumor suppressor p53 has a central role in cellular response to DNA damage and other stresses by controlling the G1/S phase transition. Activation of p53 leads to cell cycle arrest or cell senescence and/or apoptosis. In turn, loss of p53 promotes proliferation, survival, genomic instability and tumor progression. 11 Fifty percent of all human cancers contain p53 mutations.
mechanism of how the loss of p53 leads to more aggressive AML is not fully understood.
In this study, we crossed murine PU.1 knockdown model (PU.1 ure/ure ) and p53 À / À mutant mice to address the question of how loss of p53 modulates AML that is caused by a defect of PU.1. The composite PU.1 ure/ure p53 À / À mice developed highly aggressive AML that is coupled with further downregulation of PU.1. Mechanism between loss of p53 and downregulation of PU.1 seems to be indirect and involves deregulation of E-box proteins and miR-155. In addition, the described mechanism in PU.1 ure/ure p53 À / À murine AML was also observable in human AML. (Figures 1Ae-g ). AML spleens contained traces of dysplastic extramedullary haematopoiesis, from which megakaryocytes were severely dysplastic in the PU.1 ure/ure p53 À / À mice, whereas less dysplastic changes were observed in PU.1 ure/ure spleens (Figures 1Ae-g, Supplementary Figure 1 As indicated in Figure 1c and Tables 1 and 2 Figure 2 ). The preleukaemic phase, typical for PU.1 ure/ure mice, was not observed in the compound mice ( Figure 2a and Table 1 ).
RESULTS

PU
Histology examination (see Supplementary Figure 2 ure/ure mice. miR-155 represents a key regulator that post-transcriptionally downregulates PU.1 and its overexpression causes a myeloproliferative disorder in mouse. 6 We hypothesized that miR-155 is a candidate factor that could account for the repression of PU.1 in our AML models. We quantified miR-155 expression and found that it is significantly upregulated in BM-derived c-Kit þ progenitors in PU.1 ure/ure mice ( Figure 3c ). Furthermore, in PU.1 ure/ure p53 À / À mice the miR-155 level is further elevated (more than threefold, compared with WT) and is significantly higher than in PU.1 ure/ure mice. The increased levels of miR-155 were also demonstrated within the HSPCs and progenitor populations of the respective genotypes ( Figure 3c ).
Next, we determined whether the miR-155 upregulation in AML is regulated at epigenetic level. We performed chromatin immunoprecipitation at the Mir-155hg locus using antibodies against H3K9Ac, H3K9Me and H3K4Me. We observed that the chromatin state in c-Kit þ blast cells of the PU.1 ure/ure p53 À / À mice significantly differs from PU.1 ure/ure or WT mice. We detected enhanced mark of active chromatin, histone H3K9Ac, at the distal regulatory region (near À 6 kb, Figure 3d ; D-6), whereas the reciprocal state was noted at the proximal promoter (near À 0.6 kb, Figure 3d ; P-0.6,). Additionally, region D-6 was also enriched (along with D-7 and D-1.5) by H3K4Me3 (Supplementary Figure 3A) . Active marks at the amplicons D-6 and P-0.6 were reflected by inverse state of the repressive mark, H3K9 trimethylation ( Figure 3d) 
1 is a direct target of miR-155. 6 As such, the observed downregulation of PU.1 expression can be accounted for by the concurrent increase of miR-155. However, what is regulating miR-155? The E-box transcription factors MYB and MYC are associated with transcriptional regulation of miR-155. 9, 22 In accordance with these observations these two oncogenes are increased within c-Kit þ progenitors of p53 À / À mice ( Figure 3e) ; however, their levels neither stimulated miR-155 expression (Figure 3c ) nor caused AML. Furthermore, Myb, and to lower extent also Myc, are upregulated in PU.1 ure/ure HPSCs. We note upregulation of Myb at similar levels in the individual mutants (p53 À / À or PU.1 ure/ure ). Notably, Myb (as well as Myc) were further upregulated in Figure 4C) . Interestingly, the levels of miR-155 and Myb were not affected by PU.1 ectopic expression (Figure 4c ). These data indicate that while PU.1 is a downstream effector of Myb and miR-155 the reciprocal does not hold.
Next, we determined whether Myb and miR-155 are involved in the leukemic cell growth of the blast cells and whether restoration of PU.1 could block these effects. Leukemic growth of the c-Kit 
m., P-values (t-test, unpaired for immature colonies).
Aggressive AML in PU.1/p53 double-mutant mice P Basova et al cells (used in Figures 4a-c) (Figure 4d, right) , consistent with expression data (Figures  4a-c) . Interestingly, the rescue was most effective in PU.1 transfectants, confirming key importance of PU.l levels. The effect of PU.1 overexpression on PU.1 targets was further documented by FACS analysis of increased Mac1 and Gr-1 positivity in colonies formed by PU.1 ure/ure p53 À / À blasts (Supplementary Figure 4E) . Furthermore, the replating of the PU.1-transfected PU.1 ure/ure p53 À / À blasts revealed that increased PU.1 expression limited the leukemogenic potential of AML blasts (Figure 4e) .
The upregulation of both Myb and miR-155 with the downregulation of PU.1 observed in PU.1 ure/ure p53 À / À mice can be the result of either enhanced genome instability followed by clonal selection in mice after the p53 deletion or a lack of direct regulation of these factors by p53. To test these possibilities we used transient p53-siRNA knockdown. We observed, surprisingly, that the temporal inhibition of p53 level in PU.1 ure/ure progenitors to 40% affected expression of all members of the Myb/miR-155/ PU.1 axis (including PU.1 targets) as well as p53 target gene p21 (Figure 4f and Supplementary Figure 4D) . Particularly, upregulation of MYB (2-fold), upregulation of miR-155 (2-fold), downregulation of PU.1 (threefold) and simultaneous downregulation of PU.1 targets was achieved. Furthermore, p53 knockdown resulted in increased leukemic growth indicated by an increase in the number of colonies of immature cells and concurrent decrease in differentiating CFU colonies (Figure 4g ). These data indicate that p53 is directly involved in the regulation of MYB/miR-155/PU.1 mechanism and deregulation of this pathway is likely an early event after p53 mutation in PU.1 ure/ure mice. To validate that p53 regulates PU.1 at posttranscriptional level, we compared pre-mRNA and mRNA levels of PU.1 upon p53 knockdown in PU.1 ure/ure c-Kit þ blasts. Decreased levels of mRNA compared to pre-mRNA indicates indeed that PU.1 is regulated at postrancriptional levels (as pre-mRNA localized in the nucleus is not subjected to microRNA-mediated degradation that occurs in the cytoplasm) (Supplementary Figure 4D) . This section confirms that (i) both Myb and miR-155 are required for the downregulation of PU.1 levels, (ii) suggests a hierarchical order of these factors (Myb/miR-155/PU.1) during AML pathogenesis and (iii) the role of p53 loss as an upstream factor of Myb expression in aggressive AML. The manipulations of these factors-either inhibition of the oncogenes (Myb and miR-155) or rescue of PU.1-lead to leukemia blast differentiation.
Dysregulation of p53/Myb/miR-155/PU.1 pathway is observable in human AML To validate and correlate our findings from mice to human clinical AML, we determined expression of miR-155, PU.1 and E-box proteins (MYC, MYB) in a cohort of 36 AML patient peripheral blood mononuclear cell (PBMCs) and 14 healthy controls (Supplementary Figure 5A) .
Majority of patients (27 out 36, 75%) had decreased levels of PU.1 (Po0.01), with a range of two-to eightfold less compared with controls (Figures 5a and b) . First, based on the expression levels of PU.1, the AML patients were subdivided into two groups with either normal (NORM, FC log2 o À 0.5) or decreased (LOW, FC log2 4 À 0.5) PU.1 levels. Next, we compared expression of PU.1, miR-155, MYB and MYC within in each group. Interestingly, 70% patients in PU.1-LOW group showed upregulation of miR-155 (Po0.05), displaying a negative PU.1/miR-155 correlation (Spearman, r ¼ À 0.347, P ¼ 0.038; Supplementary Figure 5A) . Furthermore, the MYB oncogene (unlike MYC) was overexpressed in 96% of PU.1-LOW patients and displayed a significant negative correlation with PU.1 (r ¼ À 0.582, P ¼ 0.0006). In addition, MYB and miR-155 were positively correlated (r ¼ 0.223, P ¼ 0.069), indicating that both miR-155 and MYB cooperate in the downregulation of PU.1 in clinical AML. Additional controls including Band T-depleted PBMCs and PB-derived CD34 þ cells of healthy donors are provided in Supplementary Figure 5C .
To further elaborate on the role of p53 inactivation in human AML in relation to MYB/miR-155/PU.1 circuit, we considered the cytogenetic status of p53 in our AML patients. The deletion of 17p13 locus carrying p53 gene was found in three AML patients and strikingly all of them were among the PU.1-LOW patients with highest MYB and miR-155 expression (indicated by arrows in Figure 5b ). We note that detection of p53 deletion by FISH was limited to a few patients' samples and therefore the number of p53 deletions in the cohort of patients could be higher.
The correlation between the levels of Myb, miR-155 and expression of PU.1 in human AML may not necessarily dictate that they are directly regulating the AML aggressiveness as observed in the mice. Therefore, we used human AML cell line NB4 and manipulated levels of MYB/miR-155/PU.1 axis and p53. Knockdown of MYB decreased miR-155 and reciprocally increased PU.1; similarly as in murine AML (Figure 5c ). Knockdown of miR-155 upregulated PU.1; however, likely due to restored PU.1, it led to decreased MYB, indicating that PU.1 may function as a repressor of MYB (Figure 5d ). The PU.1 overexpression in NB4 cells resulted in the downregulation of MYB and its downstream target miR-155 (Figure 5e ). In addition, we treated NB4 cells with p53 siRNA that resulted in the derepression of MYB and miR-155 coupled with the downregulation of PU.1 and its targets (Figure 5f and Supplementary Figure 5D -G), similarly as in murine AML. These data indicate that p53/MYB/miR-155/PU.1 regulatory axis is functional in human AML.
In summary, the pathological upregulation of miR-155 and MYB in accordance with the downregulation of PU.1 expression suggests that MYB/miR-155/PU.1 regulatory circuit is among those mechanisms that contribute to the downregulation of PU.1 in a subset of human AML, especially in aggressive cases characterized by p53 inactivation.
DISCUSSION
We herein present evidence that PU.1 ure/ure p53 À / À double-mutant mice express very low PU.1 levels and develop highly aggressive AML (compared with PU.1 ure/ure mice), thus supporting the overall notion that regulation of PU.1 levels is involved in acute leukaemogenesis. Extremely low levels of PU.1 can be found in HPSCs and progenitors; however, this pattern changes markedly during myeloid development, 1 therefore low levels of PU.1 are sufficient to stimulate development up to the level of myeloid blast cells. Our current (Figures 4c and 5e ) and previous data in other AML models 23 show that complementation with PU.1 rescues myeloid differentiation of leukemic blasts. Rescue models also indicate that PU.1 at low levels is not effectively stimulating transcription of PU.1 target genes required for myelopoiesis and at the same time is not able to effectively repress oncogenic transcription factors: Myb and Myc, known activators of cell proliferation and inhibitors of myeloid maturation. 24 Compared with PU.1 ure/ure mice the double mutants develop aggressive AML that is marked by rapidly expanding and infiltrating blasts, severe anemia, thrombocytopenia associated with BM and splenic megakaryocytic dysplasia, more aggressive leukemic in vitro growth and shorter overall survival (Figures 1 and 2) . Some phenomena are however overlapping between the single-and Aggressive AML in PU.1/p53 double-mutant mice P Basova et al double-mutant AML such as surface marker expression. Observed molecular mechanisms herein associated with the AML aggressiveness (such as expression and regulatory relationships of Myb/miR-155/PU.1 axis that lead to two different PU.1 levels) appear to be present in both single-and double-mutant AML, however in the double mutants it appears to be markedly more active (Figure 3) .
AML in the PU. Aggressive AML in PU.1/p53 double-mutant mice P Basova et al consequence caused by genomic instability followed by clonal selection. Although p53 deficiency leads to multiple changes at the HSPC level such as regulation of quiescence and selfrenewal, 25 it alone is not sufficient to downregulate PU.1, upregulate miR-155 or cause AML.
Work by others suggests that PU.1 can deregulate the expression of E-box proteins. 4, 26 In accordance with these observations, our data using PU.1 overexpression in human NB4 AML cell line indicated that PU.1 is a repressor of MYB (Figure 5e ). Interestingly, in murine PU.1 ure/ure or PU.1 ure/ure p53 À / À progenitors restored expression of PU.1 did not influence Myb or miR-155 (Figure 4c ), documenting differences between murine and human AML.
We demonstrated that expression of MYB, miR-155 and PU.1 levels correlates within a relatively large proportion of human AML patients (Figures 5a and b) . At the same time we provide evidence that MYB and miR-155 functionally cooperate to downregulate PU.1 in mouse model of AML. This indicates that MYB, miR-155 and PU.1 axis is functional in human AML and represents the mechanism likely responsible for downregulation of PU.1. Interestingly, the PU.1-LOW patients with p53 deletion expressed the highest levels of miR-155 and MYB, indicating that further upregulation of MYB and miR-155 is associated with aggressive features of p53 À / À AML. The higher number of AML patients with elevated MYB (B92%) than the patients with upregulated miR-155 (58%) indicates that MYB has broader regulatory potential than miR-155 and possibly activates in AML set of other factors than solely miR-155. By in silico predictions (Targetscan.org) miR-155 has the potential to postranscriptionally downregulate B440 conserved target mRNAs. As such, in addition to PU.1, miR-155 likely downregulates other genes that can contribute to AML. Similarly, in addition to miR-155, other microRNAs that interfere with PU.1 transcriptional program are likely to contribute to AML pathology including oncogenic cluster miR-17-92 (Supplementary Discussion) 27 or miR-34 (30), both regulated by p53. Consistent with our observations, the upregulation of miR-155 as well as the downregulation of PU.1 have been previously described in human AML 6 and myelodysplasia, 28, 29 respectively. Interestingly, the role of MYB within the MYB/miR-155/PU.1 regulatory circuit is also functional in lymphoid cells derived from CLL; 9 however, histone marks analyses within the MIR-155HG indicate differences between CLL and AML tumor cells (Figure 3d,  Supplementary Figure 3A) . Despite these differences, the oncogenic circuit involving MYB, miR-155 and PU.1 may represent general mechanism that operates in HSPCs and associated with the development of several hematologic malignancies. Inhibition of miR-155 and/or restoration of PU.1 levels (Figures 5d and e) could be a valuable strategy to restore progenitor cell differentiation. Additionally, upstream factors regulating MIR-155HG transcription, such as MYB or MYC, are also candidate targets for differentiation therapy of human myeloid leukemias. 9, 22 We propose a novel mechanism for the progressive pathology of AML ( Figure 6 and more detailed Supplementary Figure 6 ). Primary AML is initiated by a dysregulation of the myeloid gene network, such as a reduction in the expression levels of the PU.1 transcription factor. Upon a 'second hit' mutation such as the loss of p53 additional dysregulation to the network occurs. Specifically, upon the loss of p53 the two oncogenes Myb and miR-155 are upregulated concomitantly with progressive PU.1 downregulation. The further downregulation of PU.1 advances the disease into a more aggressive form.
The possible scenarios are as followed: in p53 À / À mice, Myb (and also Myc) are only mildly upregulated (see In summary, we herein established a mouse model to study the role and impact of p53 loss in AML pathogenesis. We identified a candidate mechanism that is responsible for PU.1 downregulation in murine AML and showed its possible involvement in the pathogenesis and aggressiveness of human AML.
MATERIALS AND METHODS Haematology
MAgnetiC c-Kit þ Separation (Miltenyi Biotec, Bergisch Gladbach, Germany) and FACS analysis on Canto II analyzer (BD Biosciences, San Jose, CA, USA) were performed follwing the instrument's manual respectively. Flow cytometric PU.1 assay was performed as described elsewhere. 21 Details of the antibodies used for MACS, IHC and FACS are in Supplementary Information. Venous PB films (May-Gru +nwald/Giemsa-Romanowsky on LeicaBME microscope) and counts (Advia60) were determined. Fixed paraffin-embedded tissues were sliced by microtome and haematoxylin/ eosin-stained. Mouse handling and additional specific methods are extended in Supplementary materials and methods.
Transfection
